- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06557733
TPST-1495 in Patients With Familial Adenomatous Polyposis
Estudo de fase 2 para avaliar a eficácia e segurança de TPST-1495 em pacientes com polipose adenomatosa familiar (PAF)
This open-label phase II trial tests how well TPST-1495 works in reducing the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is an inherited condition in which numerous polyps (growths that protrude from mucous membranes) form on the inside walls of the colon and rectum. It increases the risk for colon cancer. TPST-1495 binds to specific prostaglandin receptors. TPST-1495 is a dual antagonist of the prostaglandin E2 (PGE2) receptor subtypes EP2 and EP4, while sparing the immune-stimulating EP1 and EP3 receptors. TPST-1495 may help reduce the number of polyps in the small bowel and colon in patients with FAP.
Visão geral do estudo
Status
Descrição detalhada
PRIMARY OBJECTIVES:
I. To assess the activity of TPST-1495 in reducing duodenal polyp burden in patients with FAP.
II. To assess the safety of TPST-1495 in patients with FAP; we will evaluate the incidence of grade 2 or 3 adverse events.
SECONDARY OBJECTIVE:
I. The activity of TPST-1495 in reducing rectum/IPAA (ileal pouch-anal anastomosis) polyp burden in patients with FAP.
EXPLORATORY OBJECTIVES:
I. Reduction in intestinal polyp burden as a function of immunohistochemical staining at baseline and end of intervention (6-months) of rectal and duodenal tissue samples for COX-2 expression level, beta-catenin, and Ki-67.
II. Proteomic profile of serum correlated to clinical response to therapy compared between baseline and end of intervention.
III. Biospecimen acquisition.
OUTLINE:
Patients receive TPST-1495 orally (PO) once daily (QD) for 6 months in the absence of unacceptable toxicity. Patients also undergo esophagogastroduodenoscopy (EGD) and gastrointestinal (GI) endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 1 month.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Recrutamento
- Mayo Clinic Hospital in Arizona
-
Contato:
- Niloy J. Samadder
- Número de telefone: 480-342-6263
- E-mail: Samadder.jewel@mayo.edu
-
Investigador principal:
- Niloy J. Samadder
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Ainda não está recrutando
- Mayo Clinic in Rochester
-
Investigador principal:
- Lisa A. Boardman
-
Contato:
- Lisa A. Boardman
- Número de telefone: 507-284-2175
- E-mail: boardman.lisa@mayo.edu
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Ainda não está recrutando
- Huntsman Cancer Institute/University of Utah
-
Contato:
- Jessica R. Stout
- Número de telefone: 801-585-6439
- E-mail: jessica.stout@utah.edu
-
Investigador principal:
- Jessica R. Stout
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Recrutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Investigador principal:
- Lisa M. Barroilhet
-
Contato:
- Lisa M. Barroilhet
- Número de telefone: 608-265-2319
- E-mail: barroilhet@wisc.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Diagnosis of familial adenomatous polyposis (FAP), defined as at least one of the following:
- Genetic diagnosis with confirmed APC mutation (clinical CLIA [clinical laboratory improvement amendments] certified lab or research testing)
- Obligate carrier
- Clinical diagnosis of classic FAP with ≥ 100 colorectal adenomas status post colectomy or a sub-total colectomy and a family history of FAP
- Clinical diagnosis of FAP, based on personal and family history. Note: This criterion requires documented review and agreement from either the study chair or the MW consortium lead investigator
-
Previously underwent prophylactic colectomy or sub-total colectomy with IRA (ileo-rectal or ileo-colonic anastomosis) or IPAA at least 12 months before pre-registration evaluation and without ongoing surgical complication
-
Willing to discontinue taking non-steroidal anti-inflammatory drugs (NSAIDs) 5 days prior to initiation of study treatment and limit frequency of NSAID dosing during study treatment
-
Age ≥ 18. Because no dosing or adverse event (AE) data are currently available on the use of TPST-1495 in participants < 18 years of age, children and adolescents are excluded from this study but will be eligible for future pediatric trials, if applicable
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
-
Leukocytes (white blood count [WBC]) ≥ 3,000/uL (≥ 2,500/uL for African American participants)
-
Platelet count ≥ 100 x 10^9/L
-
Hemoglobin ≥ 11.5 g/dL
-
Total bilirubin ≤ 1.5 x institutional upper limit normal (ULN) (unless patient has Gilbert's)
-
Alkaline phosphatase ≤ 1.5 x institutional ULN
-
Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2 x institutional ULN
-
Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) ≤ 2 x institutional ULN
-
Creatinine ≤ institutional ULN
-
Urinary testing results within institutional limits of normal or deemed clinically insignificant
-
Individuals on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
-
Presence of Spigelman 2 or 3 duodenal polyposis stage assessed by endoscopy
-
Not pregnant: The effects of TPST-1495 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation or for 90 days after stopping study agent. Additionally, men should not donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
-
Not currently breastfeeding
-
Ability to understand and the willingness to sign a written informed consent document
-
Helicobacter (H.) pylori negative confirmed with gastric biopsy (at time of screening EGD) as the preferred option. If gastric biopsies are not available or collected, sites can consider non-invasive testing options for H. pylori such as stool antigen or breath testing and invoice for that test if performed. If H. pylori status was previously assessed within 30 days of the endoscopy we would also accept the results of that test. If positive for H. pylori the patient can be offered full course of approved therapy with confirmation of eradication and re-assessment for trial participation with likely need to repeat baseline endoscopies if > 60 days since date of baseline procedures
Exclusion Criteria:
- Use of any other investigational agents ≤ 12 weeks prior to pre-registration
- History of gastric or intestinal ulceration due to NSAID therapy
- Uncontrolled intercurrent illness or recent surgical procedure that in the opinion of the investigative team would limit compliance with study requirements
- History of invasive malignancy ≤ 3 years prior to pre-registration (exception: adequately treated carcinoma of the cervix, carcinoma in situ, or basal or squamous cell carcinomas of the skin)
- History of any upper GI surgery that does not permit access to or evaluation of a 10 cm segment of the duodenum that includes the duodenal bulb, i.e. Whipple procedure or similar
- Any histologically confirmed high grade dysplasia (HGD) or cancer, gastrointestinal bleeding and requirement for anticoagulation therapy after study start except for use of low dose aspirin
- Exclusion of patients utilizing strong a moderate inhibitors of CYP2D6 and CYP3A4
- Individuals with evidence of human immunodeficiency virus (HIV) infection will be excluded from the study even if the HIV viral load is undetectable on suppressive therapy. Many of the HIV suppression anti-viral medications are moderate/strong inhibitors of CYP2D6 and CYP3A4 and are exclusions based on above
- Individuals with evidence of chronic hepatitis B virus (HBV) or C virus (HCV) infection will be excluded from the study, even if the HBV/HCV viral load is undetectable on suppressive therapy. Many of the HBV/HCV suppression anti-viral medications are moderate/strong inhibitors of CYP2D6 and CYP3A4 and are exclusions based on above
- Individuals with active H. pylori infection that is untreated or refractory to standard antibiotic therapy
- Patients with prior history of peptic ulcers complicated by bleeding, New York Heart Association (NYHA) Classification II-IV, active autoimmune diseases, on anticoagulants at risk of bleeding or abnormal corrected QT interval (QTc) prolongation will also be excluded. Patients enrolled in this trial are status post colectomy or subtotal colectomy (with either IPAA or IRA or ileo-colonic anastomosis) and thus would not be expected to be at significant risk of diverticulitis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Prevention (TPST-1495)
Patients receive TPST-1495 PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo EGD and GI endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study. |
Undergo blood sample collection
Outros nomes:
Ancillary studies Undergo biopsy
Outros nomes:
Undergo EGD
Outros nomes:
Given PO
Outros nomes:
Undergo GI endoscopy |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent change in duodenal polyp burden
Prazo: Baseline to 6 months
|
Will be determined based on the sum of diameters from all polyps. Will be assessed by comparing upper gastrointestinal (GI) endoscopies respectively. Will be described using a two-sided 95% confidence interval and examined for difference from zero with a one-side paired t-test. |
Baseline to 6 months
|
|
Incidence of adverse events
Prazo: Up to 7 months
|
Will examine the proportion of patients with grade 2 or 3 adverse events according to the Common Terminology Criteria for Adverse Events version 6.0. Will be summarized as a proportion with a 1-sided 90% confidence interval. |
Up to 7 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent change in rectal/pouch polyp burden
Prazo: Baseline to 6 months
|
Will be assessed by comparing the lower GI endoscopies. Results will be presented using summary statistics and corresponding confidence intervals. |
Baseline to 6 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent change in immunohistochemical staining levels
Prazo: Baseline to 6 months
|
Will assess rectal and duodenal tissue samples for COX-2 expression level, beta-catenin, and Ki-67. Mean percent change in immunohistochemical staining levels will be associated with intestinal polyp burden using a scatterplot of the two variables and evaluated using a Spearman rank correlation statistic. |
Baseline to 6 months
|
|
Proteomic profile
Prazo: Baseline to 6 months
|
Will identify proteins that are statistically significantly differently expressed between patients after treatment. The proteomic profile of serum will be correlated to clinical response to therapy and compared between baseline and end of intervention. No formal statistical inference will be performed. Proteins will be described with summary statistics to assist in planning follow-up studies. |
Baseline to 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Niloy J Samadder, University of Wisconsin Carbone Cancer Center - University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Genéticas, Congênitas
- Doenças Intestinais
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Neoplasias Glandulares e Epiteliais
- Doenças do cólon
- Adenoma
- Síndromes Neoplásicas Hereditárias
- Pólipos adenomatosos
- Polipose Intestinal
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Neoplasias Colorretais
- Polipose Adenomatosa Coli
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Procedimentos cirúrgicos minimamente invasivos
- Técnicas citológicas
- Citodiagnóstico
- Técnicas de diagnóstico, cirúrgico
- Técnicas de diagnóstico, sistema digestivo
- Endoscopia
- Procedimentos cirúrgicos do sistema digestivo
- Biópsia
- Manipulação de amostras
- Endoscopia, gastrointestinal
- Endoscopia, sistema digestivo
- Gastroscopia
Outros números de identificação do estudo
- NCI-2024-06758
- P30CA014520 (Concessão/Contrato do NIH dos EUA)
- UG1CA242596 (Concessão/Contrato do NIH dos EUA)
- UG1CA242635 (Concessão/Contrato do NIH dos EUA)
- NCI-2024-06758 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- UWI23-16-01 (Outro identificador: DCP)
- UWI23-16-01 (Outro identificador: University of Wisconsin Carbone Cancer Center - University Hospital)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .